In general, the earlier the cancer is diagnosed the more effective the treatments are at preventing recurrence of breast cancer.

Lindsay Fry is a breast cancer survivor who was first diagnosed in 2019. Her treatment regimen of surgery, radiation and chemotherapy began in fall 2019. Shortly after completing her treatment, Fry became the first participant in a new clinical trial at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) that aims to help breast cancer survivors regain their energy and remain cancer free.

What if a daily or weekly blood sample could monitor each patient’s risk of metastasis, indicating the need for aggressive therapy before cancer spread is established? That’s the ultimate goal of studies published by researchers from The University of Texas Health Science Center at San Antonio.

Brianna Garcia wondered why her heart raced when she exercised and why she was tired all the time. Her doctor in Laredo referred her to a team of specialists at UT Health San Antonio. Six weeks of care followed and experts unraveled the teen’s medical mystery.

An MRI scan called restriction spectrum imaging greatly improves the detection of prostate cancer progression, according to a published study by researchers at The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio.

David Gius, MD, PhD, has been awarded a $1.6 million UT System Faculty STARs award to support his research on aging and breast cancer.

Shaun K. Olsen, PhD, has been awarded a $1 million UT System Faculty STARs award to conduct innovative research to better understand the molecular mechanisms of diseases and advance drug discovery efforts for treatment.

Cancer research at UT Health San Antonio is getting a $23 million boost from the Cancer Prevention and Research Institute of Texas (CPRIT).

USA Paralympics sitting volleyball player Jillian Williams, who beat Ewing sarcoma with help from San Antonio and Houston medical teams, is going for the gold in the Tokyo Paralympics.

In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.